Optimizing outcomes in depression: Focus on antidepressant compliance

Martin B. Keller, R. M A Hirschfeld, K. Demyttenaere, D. S. Baldwin

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Major depressive disorder is a chronic and recurrent illness that is associated with significant morbidity and mortality. Patients frequently experience recurrent depressive episodes that are of longer duration and increased severity and which are less responsive to treatment than the index episode. Despite the highly prevalent nature of the illness, depression is frequently unrecognized and undertreated. Compliance with antidepressant medication is essential to consolidate treatment response and prevent relapse and recurrence. However, compliance with antidepressant medication is poor. Education of the patient and physician regarding the nature of depression and its treatment is essential for improving patient compliance. Although psychological mechanisms are a major factor affecting patient compliance, speed of onset of action and poor tolerability of antidepressant medication also have a considerable influence on patient compliance. The newer antidepressants, such as selective serotonin reuptake inhibitors, nonselective serotonin-norepinephrine reuptake inhibitors, and the selective norepinephrine reuptake inhibitors, are better tolerated than tricyclic antidepressants, possibly resulting in improved compliance and treatment outcome.

Original languageEnglish (US)
Pages (from-to)265-271
Number of pages7
JournalInternational Clinical Psychopharmacology
Volume17
Issue number6
StatePublished - Nov 2002

Fingerprint

Antidepressive Agents
Compliance
Patient Compliance
Depression
Recurrence
Tricyclic Antidepressive Agents
Major Depressive Disorder
Serotonin Uptake Inhibitors
Patient Education
Norepinephrine
Chronic Disease
Therapeutics
Psychology
Morbidity
Physicians
Mortality

Keywords

  • Depression
  • Efficacy
  • Selective noradenaline reuptake inhibitor
  • Selective serotonin reuptake inhibitors
  • Social functioning
  • Tolerability
  • Treatment compliance
  • Tricyclic antidepressants

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Keller, M. B., Hirschfeld, R. M. A., Demyttenaere, K., & Baldwin, D. S. (2002). Optimizing outcomes in depression: Focus on antidepressant compliance. International Clinical Psychopharmacology, 17(6), 265-271.

Optimizing outcomes in depression : Focus on antidepressant compliance. / Keller, Martin B.; Hirschfeld, R. M A; Demyttenaere, K.; Baldwin, D. S.

In: International Clinical Psychopharmacology, Vol. 17, No. 6, 11.2002, p. 265-271.

Research output: Contribution to journalArticle

Keller, MB, Hirschfeld, RMA, Demyttenaere, K & Baldwin, DS 2002, 'Optimizing outcomes in depression: Focus on antidepressant compliance', International Clinical Psychopharmacology, vol. 17, no. 6, pp. 265-271.
Keller MB, Hirschfeld RMA, Demyttenaere K, Baldwin DS. Optimizing outcomes in depression: Focus on antidepressant compliance. International Clinical Psychopharmacology. 2002 Nov;17(6):265-271.
Keller, Martin B. ; Hirschfeld, R. M A ; Demyttenaere, K. ; Baldwin, D. S. / Optimizing outcomes in depression : Focus on antidepressant compliance. In: International Clinical Psychopharmacology. 2002 ; Vol. 17, No. 6. pp. 265-271.
@article{1c3d29d2f7cc4b6aaf988c23ca57f5e9,
title = "Optimizing outcomes in depression: Focus on antidepressant compliance",
abstract = "Major depressive disorder is a chronic and recurrent illness that is associated with significant morbidity and mortality. Patients frequently experience recurrent depressive episodes that are of longer duration and increased severity and which are less responsive to treatment than the index episode. Despite the highly prevalent nature of the illness, depression is frequently unrecognized and undertreated. Compliance with antidepressant medication is essential to consolidate treatment response and prevent relapse and recurrence. However, compliance with antidepressant medication is poor. Education of the patient and physician regarding the nature of depression and its treatment is essential for improving patient compliance. Although psychological mechanisms are a major factor affecting patient compliance, speed of onset of action and poor tolerability of antidepressant medication also have a considerable influence on patient compliance. The newer antidepressants, such as selective serotonin reuptake inhibitors, nonselective serotonin-norepinephrine reuptake inhibitors, and the selective norepinephrine reuptake inhibitors, are better tolerated than tricyclic antidepressants, possibly resulting in improved compliance and treatment outcome.",
keywords = "Depression, Efficacy, Selective noradenaline reuptake inhibitor, Selective serotonin reuptake inhibitors, Social functioning, Tolerability, Treatment compliance, Tricyclic antidepressants",
author = "Keller, {Martin B.} and Hirschfeld, {R. M A} and K. Demyttenaere and Baldwin, {D. S.}",
year = "2002",
month = "11",
language = "English (US)",
volume = "17",
pages = "265--271",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Optimizing outcomes in depression

T2 - Focus on antidepressant compliance

AU - Keller, Martin B.

AU - Hirschfeld, R. M A

AU - Demyttenaere, K.

AU - Baldwin, D. S.

PY - 2002/11

Y1 - 2002/11

N2 - Major depressive disorder is a chronic and recurrent illness that is associated with significant morbidity and mortality. Patients frequently experience recurrent depressive episodes that are of longer duration and increased severity and which are less responsive to treatment than the index episode. Despite the highly prevalent nature of the illness, depression is frequently unrecognized and undertreated. Compliance with antidepressant medication is essential to consolidate treatment response and prevent relapse and recurrence. However, compliance with antidepressant medication is poor. Education of the patient and physician regarding the nature of depression and its treatment is essential for improving patient compliance. Although psychological mechanisms are a major factor affecting patient compliance, speed of onset of action and poor tolerability of antidepressant medication also have a considerable influence on patient compliance. The newer antidepressants, such as selective serotonin reuptake inhibitors, nonselective serotonin-norepinephrine reuptake inhibitors, and the selective norepinephrine reuptake inhibitors, are better tolerated than tricyclic antidepressants, possibly resulting in improved compliance and treatment outcome.

AB - Major depressive disorder is a chronic and recurrent illness that is associated with significant morbidity and mortality. Patients frequently experience recurrent depressive episodes that are of longer duration and increased severity and which are less responsive to treatment than the index episode. Despite the highly prevalent nature of the illness, depression is frequently unrecognized and undertreated. Compliance with antidepressant medication is essential to consolidate treatment response and prevent relapse and recurrence. However, compliance with antidepressant medication is poor. Education of the patient and physician regarding the nature of depression and its treatment is essential for improving patient compliance. Although psychological mechanisms are a major factor affecting patient compliance, speed of onset of action and poor tolerability of antidepressant medication also have a considerable influence on patient compliance. The newer antidepressants, such as selective serotonin reuptake inhibitors, nonselective serotonin-norepinephrine reuptake inhibitors, and the selective norepinephrine reuptake inhibitors, are better tolerated than tricyclic antidepressants, possibly resulting in improved compliance and treatment outcome.

KW - Depression

KW - Efficacy

KW - Selective noradenaline reuptake inhibitor

KW - Selective serotonin reuptake inhibitors

KW - Social functioning

KW - Tolerability

KW - Treatment compliance

KW - Tricyclic antidepressants

UR - http://www.scopus.com/inward/record.url?scp=0036841082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036841082&partnerID=8YFLogxK

M3 - Article

C2 - 12409679

AN - SCOPUS:0036841082

VL - 17

SP - 265

EP - 271

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 6

ER -